Patents by Inventor Patrick Schlievert

Patrick Schlievert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antimicrobial and antiviral sulfur containing glycerol monoester derivatives
    Patent number: 11873272
    Abstract: The disclosure relates generally novel sulfur containing glycerol mono-ester derivatives and methods useful for treating gram positive, gram negative, fungal and envelope viral infections in a patient.
    Type: Grant
    Filed: January 31, 2023
    Date of Patent: January 16, 2024
    Assignee: Niche Biopharmaceuticals LLC
    Inventors: Dayton T. Reardan, Paul Brennan, Patrick Schlievert
  • ANTIMICROBIAL AND ANTIVIRAL SULFUR CONTAINING GLYCEROL MONOESTER DERIVATIVES
    Publication number: 20230174473
    Abstract: The disclosure relates generally novel sulfur containing glycerol mono-ester derivatives and methods useful for treating gram positive, gram negative, fungal and envelope viral infections in a patient.
    Type: Application
    Filed: January 31, 2023
    Publication date: June 8, 2023
    Applicant: Niche Biopharmaceuticals LLC
    Inventors: Dayton T. Reardan, Paul Brennan, Patrick Schlievert
  • Antimicrobial and antiviral sulfur containing glycerol monoester derivatives
    Patent number: 11572342
    Abstract: The disclosure relates generally novel sulfur containing glycerol mono-ester derivatives and methods useful for treating gram positive, gram negative, fungal and envelope viral infections in a patient.
    Type: Grant
    Filed: September 18, 2020
    Date of Patent: February 7, 2023
    Assignee: Niche Biopharmaceuticals LLC
    Inventors: Dayton T. Reardan, Paul Brennan, Patrick Schlievert
  • Antimicrobial and antiviral sulfur containing glycerol monoester derivatives
    Patent number: 11365176
    Abstract: The disclosure relates generally novel sulfur containing glycerol mono-ester derivatives and methods useful for treating gram positive, gram negative, fungal and envelope viral infections in a patient.
    Type: Grant
    Filed: January 6, 2022
    Date of Patent: June 21, 2022
    Assignee: Niche Biopharmaceuticals LLC
    Inventors: Dayton T. Reardan, Paul Brennan, Patrick Schlievert
  • ANTIMICROBIAL AND ANTIVIRAL SULFUR CONTAINING GLYCEROL MONOESTER DERIVATIVES
    Publication number: 20220127224
    Abstract: The disclosure relates generally novel sulfur containing glycerol mono-ester derivatives and methods useful for treating gram positive, gram negative, fungal and envelope viral infections in a patient.
    Type: Application
    Filed: January 6, 2022
    Publication date: April 28, 2022
    Inventors: Dayton T. Reardan Ph.D., Paul Brennan, Patrick Schlievert
  • ANTIMICROBIAL AND ANTIVIRAL SULFUR CONTAINING GLYCEROL MONOESTER DERIVATIVES
    Publication number: 20220089535
    Abstract: The disclosure relates generally novel sulfur containing glycerol mono-ester derivatives and methods useful for treating gram positive, gram negative, fungal and envelope viral infections in a patient.
    Type: Application
    Filed: September 18, 2020
    Publication date: March 24, 2022
    Inventors: Dayton T. Reardan, Paul Brennan, Patrick Schlievert
  • ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE
    Publication number: 20150224066
    Abstract: The disclosure relates to antibiotic compositions and methods of use thereof in a mammal. In certain embodiments, the present invention provides an antimicrobial composition comprising a non-aqueous carrier and an active agent, wherein the active agent is menadione, 1,4-naphthoquinone, Coenzyme Q1, Coenzyme Q2, Coenzyme Q3, Coenzyme Q4, Coenzyme Q5, Coenzyme Q6, Coenzyme Q7, Coenzyme Q8, Coenzyme Q9, and/or Coenzyme Q10, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 14, 2013
    Publication date: August 13, 2015
    Applicant: UNIVERSITY OF IOWA RESEARCH FOUNDATION
    Inventor: Patrick Schlievert
  • Treatment of Diseases Caused by Bacterial Exotoxins
    Publication number: 20120245079
    Abstract: Provided are high affinity T cell receptor variable regions that are useful for treating diseases caused by superantigens including atopic dermatitis, pneumonia and delayed wound healing. The variable regions contain mutants that result in high affinity binding to the superantigen.
    Type: Application
    Filed: September 3, 2010
    Publication date: September 27, 2012
    Inventors: David M. Kranz, Patrick Schlievert
  • Neutralizing Agents for Bacterial Toxins
    Publication number: 20110245153
    Abstract: Stabilized variable regions of the T cell receptor and methods of making the same using directed evolution through yeast display are provided. In one embodiment, the variable region is variable beta. In one embodiment, the stabilized T cell receptor variable regions have high affinity for a superantigen, such as TSST-1 or SEB. These T cell receptor variable regions are useful as therapeutics.
    Type: Application
    Filed: March 15, 2007
    Publication date: October 6, 2011
    Applicant: National Institutes of Health (NIH), U. S. Dept. of Health and Human Resources (DHHS) U. S. Govt.
    Inventors: David M. Kranz, Rebecca A. Buonpane, Hywyn R.O. Churchill, Eric J. Sundberg, Beenu Moza, Patrick Schlievert
  • Regulation of Cell Membrane-Mediated Effects
    Publication number: 20070276049
    Abstract: The invention features methods of inhibiting cell membrane-mediated effects of infectious microorganisms and of a variety of factors on vertebrate cells with one or more of a family of glycerol-based compounds. The cell membrane-mediated s effects are those resulting in, for example, infection of the vertebrate cells by relevant infectious microorganisms and inflammatory responses to infectious microorganisms or factors.
    Type: Application
    Filed: November 10, 2004
    Publication date: November 29, 2007
    Inventors: Patrick Schlievert, Marnie Peterson
  • Mutants of streptococcal toxin a and methods of use
    Publication number: 20060039925
    Abstract: This invention is directed to mutant SPE-A toxins or fragments thereof, vaccine and pharmaceutical compositions, and methods of using the vaccine and pharmaceutical compositions. The preferred SPE-A toxin has at least one amino acid change and is substantially non-lethal compared with the wild type SPE-A toxin. The mutant SPE-A toxins can form vaccine compositions useful to protect animals against the biological activities of wild type SPE-A toxin.
    Type: Application
    Filed: March 21, 2005
    Publication date: February 23, 2006
    Applicant: Regents of the University of Minnesota
    Inventors: Patrick Schlievert, Manuela Roggiani, Jennifer Stoehr, Douglas Ohlendorf
  • Mutants of streptococcal toxin A and methods of use
    Publication number: 20060041107
    Abstract: This invention is directed to mutant SPE-A toxins or fragments thereof, vaccine and pharmaceutical compositions, and methods of using the vaccine and pharmaceutical compositions. The preferred SPE-A toxin has at least one amino acid change and is substantially non-lethal compared with the wild type SPE-A toxin. The mutant SPE-A toxins can form vaccine compositions useful to protect animals against the biological activities of wild type SPE-A toxin.
    Type: Application
    Filed: July 5, 2005
    Publication date: February 23, 2006
    Applicant: Regents of the University of Minnesota
    Inventors: Patrick Schlievert, Manuela Roggiani, Jennifer Auge, Douglas Ohlendorf
  • Compositions and methods for controlling infections
    Publication number: 20060029558
    Abstract: The invention features methods of inhibiting the growth of, or killing, fungal and certain bacterial microorganisms with one or more of a family of glycerol-based compounds.
    Type: Application
    Filed: August 2, 2005
    Publication date: February 9, 2006
    Inventors: Patrick Schlievert, Marnie Peterson
  • Regulation of cell membrane-mediated effects
    Publication number: 20050215634
    Abstract: The invention features methods of inhibiting cell membrane-mediated effects of infectious microorganisms and of a variety of factors on vertebrate cells with one or more of a family of glycerol-based compounds. The cell membrane-mediated effects are those resulting in, for example, infection of the vertebrate cells by relevant infectious microorganisms and inflammatory responses to infectious microorganisms or factors.
    Type: Application
    Filed: November 10, 2004
    Publication date: September 29, 2005
    Inventors: Patrick Schlievert, Marnie Peterson
  • Mutants of streptococcal toxin C and methods of use
    Publication number: 20050010034
    Abstract: This invention is directed to mutant SPE-C toxins or fragments thereof, vaccine and pharmaceutical compositions, and methods of using the vaccine and pharmaceutical compositions. The preferred SPE-C toxin has at least one amino acid change and is substantially non-lethal compared with the wild type SPE-C toxin. The mutant SPE-C toxins can form vaccine compositions useful to protect animals against the biological activities of wild type SPE-C toxin.
    Type: Application
    Filed: August 9, 2004
    Publication date: January 13, 2005
    Applicant: Regents of the University of Minnesota
    Inventors: Patrick Schlievert, Douglas Ohlendorf, David Mitchell, Pamala Gahr
  • Mutants of streptococcal toxin C and methods of use
    Publication number: 20050010033
    Abstract: This invention is directed to mutant SPE-C toxins or fragments thereof, vaccine and pharmaceutical compositions, and methods of using the vaccine and pharmaceutical compositions. The preferred SPE-C toxin has at least one amino acid change and is substantially non-lethal compared with the wild type SPE-C toxin. The mutant SPE-C toxins can form vaccine compositions useful to protect animals against the biological activities of wild type SPE-C toxin.
    Type: Application
    Filed: August 9, 2004
    Publication date: January 13, 2005
    Applicant: Regents of the University of Minnesota
    Inventors: Patrick Schlievert, Douglas Ohlendorf, David Mitchell, Pamala Gahr
  • Isolated toxin associated with Kawasaki syndrome
    Patent number: 5585465
    Abstract: The invention relates to the isolated toxin associated with Kawasaki syndrome and the bacteria from which these are isolated.
    Type: Grant
    Filed: May 12, 1995
    Date of Patent: December 17, 1996
    Assignees: National Jewish Center for Immunology and Respiratory Medicine, New England Medical Center Hospital, Inc., Regents of the University of Minnesota
    Inventors: Donald Leung, Patrick Schlievert, Cody Meissner
  • Isolated nucleic acid molecule coding for toxin associated with Kawasaki Syndrome and uses thereof
    Patent number: 5476767
    Abstract: The invention relates to isolated nucleic acid molecules coding for toxins associated with Kawasaki Syndrome. Also described are various applications of the nucleic acid molecules.
    Type: Grant
    Filed: November 12, 1993
    Date of Patent: December 19, 1995
    Assignees: Regents of the University of Minnesota, New England Medical Center Hospital, Inc., National Jewish Center for Immunology and Respiratory Medicine
    Inventors: Donald Leung, Patrick Schlievert, Cody Meissner, David Fulton
  • Method for diagnosing kawasaki syndrome
    Patent number: 5470716
    Abstract: The invention relates to various methodologies for diagnosing Kawasaki syndrome. Various bacteria, including TSST-1 producing Staphylococcus aureus, and SPEB and SPEC producing streptococcus have been found to be indicative of the pathological condition. Also described is a Kawasaki syndrome implicated isolate of S. aureus, and therapeutic methodologies for preventing treating the condition.
    Type: Grant
    Filed: April 5, 1993
    Date of Patent: November 28, 1995
    Assignees: National Jewish Center For Immunology and Respiratory Medicine, New England Medical Center Hospital, Inc., University of Minnesota, Regents of the University of Minnesota
    Inventors: Donald Leung, Patrick Schlievert, Cody Meissner, David Fulton
  • Method for treating Kawasaki syndrome by administration of an anti-TSST-1 agent which is not gamma globulin
    Patent number: 5460813
    Abstract: The invention relates to various methodologies for diagnosing Kawasaki syndrome. Various bacteria, including TSST-1 producing Staphylococcus aureus, and SPEB and SPEC producing streptococcus have been found to be indicative of the pathological condition. Also described is a Kawasaki syndrome implicated isolate of S. aureus, and therapeutic methodologies for preventing treating the condition. These involve the administration of anti-TSST-1 agents which are not gamma globulin.
    Type: Grant
    Filed: April 5, 1993
    Date of Patent: October 24, 1995
    Assignee: National Jewish Center for Immunology and Respiratory Medicine
    Inventors: Donald Leung, Patrick Schlievert, Cody Meissner, David Fulton, Brian Kotzin